



Scan to download a copy of this poster

# The effect of Erenumab on sick leave days and healthcare visits in patients with migraine in Finland

**Markku Nissilä<sup>1</sup>, Samu Kurki<sup>1</sup>, Timo Purmonen<sup>2</sup>, Minna A. Korolainen<sup>2\*</sup>, Emina Mocevic Lazzeri Erichsen<sup>3</sup>, Samuli Tuominen<sup>4</sup>, Mariann I. Lassenius<sup>4</sup>, Henri Autio<sup>2</sup>**

<sup>1</sup> Terveystalo Biobank and Clinical Research, Finland

<sup>2</sup> Novartis, Espoo, Finland

<sup>3</sup> Novartis, Copenhagen, Denmark

<sup>4</sup> Medaffcon Oy, Espoo, Finland

\* Previously employed by Novartis, Espoo, Finland

2021 EAN Annual Meeting, June 19-22 | virtual

**MN** — employee in Terveystalo, has received a speaker honorarium and research funding from Novartis and Eli Lilly and research funding from Lundbeck, Amgen and Teva.

**ML, ST**— employees in Medaffcon

**MK** — employee in Novartis at study initiation


**TP, EMLE, HA** — employees in Novartis.

**Funding source:** This study is funded by Novartis Finland Oy, Espoo, Finland. Erenumab is co-developed by Amgen and Novartis.

**Acknowledgment:** Medical writing and design support by Bettina Mannerström, Medaffcon, Espoo, Finland. The final responsibility for the content lies with the authors.



## Results



Patients who were treated with erenumab had **A) significant reduction in headache related sick leave days, a decrease of 74% from the 12 months pre vs. post index** (pre vs. post 12 months: 4.9 vs. 1.3 sick leave days per patient-year,  $p=0.035$ ). The change in headache related sick leave days and visits at 6-12 months was similar to the full 12 months post-index results. There were no changes in the headache related or overall sick leave days nor visits in the control group. **B) Headache related visits decreased by 45% from the 12 months pre vs. post index** (pre vs. post 12 months: 4.9 vs. 2.7 visits per patient-year,  $p<0.001$ ).

## Conclusions

This real-world registry study showed that treatment with erenumab **reduced headache related sick leave days by 74%**, and **headache related visits by 45%** at 12 months after treatment initiation in working aged patients with migraine.

12 months post erenumab initiation the patients had...

**73.9 %**  
FEWER SICK DAYS DUE  
TO HEADACHE

**44.6 %**  
FEWER HEADACHE-RELATED  
VISITS TO DOCTOR

...than in the previous year